Volumetric parameters on 18F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET

• Published in: BMC cancer 2019-08, Vol.19 (1), p.790-790, Article 790
• Main Authors: Liu, Guobing, Hu, Yan, Cheng, Xi, Wang, Yan, Gu, Yushen, Liu, Tianshu, Shi, Hongcheng
• Format: Article
• Language: English
• Subjects: 18F-FDG; 2-[18F] Fluoro-2-deoxy-D-glucose; Cancer metastasis; Cancer patients; Cancer research; Care and treatment; CAT scans; Diagnosis; Gastric cancer; Gastrointestinal diseases; Genetic aspects; Glucose; Glucose metabolism; Immunohistochemistry; Medical research; Operating systems (Software); Phenols (Class of compounds); Physiological aspects; Positron emission tomography; Positron emission tomography/computed tomography (PET/CT); Prognosis; Protein-tyrosine kinase; Sport utility vehicles; Stomach cancer; Tomography; Tumors; Tyrosine
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-019-5935-3

Background This study aimed to investigate the prognostic value of volumetric parameters on .sup.18F- fluoro-2-deoxy-D-glucose (.sup.18F-FDG) positron emission tomography/computed tomography (PET/CT) in gastric-cancer patients, according to the expression status of c-MET (MET proto-oncogene, receptor tyrosine kinase), which was previously unclear. Methods The study included 61 patients with advanced gastric cancer. Data on the baseline .sup.18F-FDG PET/CT, clinical-pathological information, progression-free survival (PFS), and overall survival (OS) were collected. The maximum standardized uptake value (SUV.sub.max), peak SUV (SUV.sub.peak), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of gastric tumors in situ were measured on PET/CT. The expression status of c-MET was recorded based on immunohistochemical staining. Associations between the parameters on PET/CT and patients' survival outcomes were analyzed in relation to expression status of c-MET. Results Patients with positive c-MET expression had significantly shorter PFS (11.5 vs. 17.6 months, P = 0.039) and OS (17.0 vs. 24.3 months, P = 0.043), and had gastric tumors with a larger MTV (70.8 [+ or -] 53.11 vs. 41.1 [+ or -] 52.32, P = 0.034) and TLG (428.39 [+ or -] 442.95 vs. 205.7 [+ or -] 354.40, P = 0.039), compared with those with negative c-MET expression. However, SUV.sub.max (9.6 [+ or -] 7.40 vs. 8.0 [+ or -] 4.91, P = 0.335) and SUV.sub.peak (7.7 [+ or -] 5.99 vs. 6.62 [+ or -] 4.08, P = 0.438) were similar between these two patient groups. In patients with c-MET-positive tumors, MTV and TLG were independent factors in predicting patient OS after correction by distant metastasis (hazards ratio = 1.014 and 1.002, respectively; P = 0.024 and 0.027, respectively), while these associations were not significant in patients with c-MET-negative tumors. Conclusions Patients with c-MET-positive gastric cancer had higher MTV and TLG values compared to those with c-MET-negative gastric cancer. In patients with c-MET-positive gastric cancer, volumetric parameters on .sup.18F-FDG PET/CT have prognostic value for patient overall survival. Keywords: Gastric cancer, Prognosis, 2-[18F] Fluoro-2-deoxy-D-glucose, .sup.18F-FDG, Positron emission tomography/computed tomography (PET/CT)